Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Experts warn that pharmaceutical companies are prioritizing lucrative weight-loss drugs like Ozempic and Mounjaro over essential diabetes treatments like insulin. This shift could lead to supply shortages for patients in lower-income countries.
Why it matters
The prioritization of high-profit lifestyle medications over life-saving chronic disease treatments raises significant ethical and public health concerns.
Pharma firms can charge far higher prices for GLP-1 drugs including Mounjaro, Wegovy and Ozempic than for diabetes treatments such as insulin. Pharma firms can charge far higher prices for GLP-1 drugs including Mounjaro, Wegovy and Ozempic than for diabetes treatments such as insulin. Pharmaceuticals industry Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment
Prefer the Guardian on Google The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in